Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults

Cressey, T. R.; Hazra, R.; Wiznia, A.; Foca, M.; Jean-Philippe, P.; Graham, B.; King, J. R.; Britto, P.; Carey, V. J.; Acosta, E. P.; Yogev, R.

Pediatr Infect Dis J. 2016 Sep 2; 35(12):1333-1335

Abstract

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

Read More on PubMed